Psoriasis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Psoriasis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month2 studies across 2 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| OGN | Organon and Co | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsNCT05172726Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 3 | Active, not recruiting | Oct 2026 | ≤ 72 d | 2026-04-17 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their OffspringNCT06710470observationalNumber of infants born with Major Congenital Malformations (MCMs) | — | Active, not recruiting | 2027-01-31 | in 164 d | 2024-11-29 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Psoriasis
most recently updated first346 studies match. Showing the first 100 of 346 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisNCT04772079Observed average concentration at steady state for deucravacitinib at Week 2 | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo matching deucravacitinib | Plaque Psoriasis | 153 | 2021-03-23 | 2029-01-01 | in 865 d | 2026-08-18 |
| LLY | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | $1.15T | A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT06602219results2026-08-18Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 (LY4100511 Versus Placebo) | Phase 2 | Completed | Drug: LY4100511, Placebo | Plaque Psoriasis | 222 | 2024-10-25 | 2025-07-24actual | — | 2026-08-18 |
| ORKA | Oruka Therapeutics, Inc. | $7.5B | Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07290569Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16 | Phase 2 | Active, not recruiting | Drug: ORKA-001 · Other: Placebo | Plaque Psoriasis | 160 | 2025-12-03 | Jun 2027 | ≤ 314 d | 2026-08-17 |
| SNGX | Soligenix | $9M | Topical SGX302 for Mild-to-Moderate PsoriasisNCT05442190Number of patients that achieve a 0 or 1 score using the 5-point Investigator's Global Assessment scale | Phase 2 | Completed | Drug: Hypericin | Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris | 15 | 2022-12-14 | 2025-10-22actual | — | 2026-08-13 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque PsoriasisNCT06979453Number of participants achieving at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) | Phase 3 | Recruiting | Drug: Deucravacitinib · Other: Placebo | Plaque Psoriasis | 366 | 2025-12-03 | 2029-10-12 | in 1,149 d | 2026-08-11 |
| ALMS | Alumis Inc | $2.1B | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque PsoriasisNCT06586112To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo | Phase 3 | Completed | Drug: Envudeucitinib, Apremilast, Placebo | Plaque Psoriasis | 912 | 2024-07-25 | 2025-09-19actual | — | 2026-08-10 |
| ALMS | Alumis Inc | $2.1B | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001NCT06588738To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo | Phase 3 | Completed | Drug: Envudeucitinib, Placebo, Apremilast | Plaque Psoriasis | 862 | 2024-08-20 | 2025-09-23actual | — | 2026-08-10 |
| ORKA | Oruka Therapeutics, Inc. | $7.5B | Dose Ranging Study of ORKA-002 in Patients With Moderate-to-Severe Plaque PsoriasisNCT07474792Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16 | Phase 2 | Recruiting | Drug: ORKA-002 · Other: Placebo | Plaque Psoriasis | 160 | 2026-03-19 | Oct 2027 | ≤ 437 d | 2026-08-10 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216)NCT04746911results2026-08-07Plasma Concentration of Roflumilast Following Daily Application of Roflumilast Cream 0.3% | Phase 2 | Completed | Drug: ARQ-151 cream 0.3% | Psoriasis, Plaque Psoriasis | 10 | 2021-03-01 | 2022-05-11actual | — | 2026-08-07 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT07039110observationalProportion of participants achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1 | — | Recruiting | — | Plaque Psoriasis | 700 | 2025-09-09 | Mar 2028 | ≤ 589 d | 2026-08-05 |
| ORKA | Oruka Therapeutics, Inc. | $7.5B | An Open-Label Extension Study of ORKA-001 in Participants With Plaque PsoriasisNCT07449702Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs) | Phase 2 | Recruiting | Drug: ORKA-001 | Plaque Psoriasis | 240 | 2026-02-23 | May 2030 | ≤ 1,380 d | 2026-08-05 |
| ALMS | Alumis Inc | $2.1B | Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque PsoriasisNCT05739435To assess the safety and tolerability of long-term ESK-001 treatment | Phase 2 | Active, not recruiting | Drug: envudeucitinib | Plaque Psoriasis | 165 | 2023-01-17 | 2027-12-01 | in 468 d | 2026-07-28 |
| BMY | Bristol-Myers Squibb | $134.9B | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)NCT07116967Composite cardiovascular adjudicated 3-point major adverse cardiovascular event (MACE) plus coronary revascularization | Phase 3 | Recruiting | Drug: Deucravacitinib, Ustekinumab | Plaque Psoriasis | 3,040 | 2025-09-22 | 2031-01-16 | in 1,610 d | 2026-07-23 |
| AMGN | Amgen | $229.9B | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque PsoriasisNCT05565560Achievement of a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) with at least 2 points reduction from baseline at Week 16 | Phase 3 | Active, not recruiting | Drug: Apremilast | Plaque Psoriasis | 17 | 2023-01-25 | 2025-11-20actual | — | 2026-07-15 |
| ORKA | Oruka Therapeutics, Inc. | $7.5B | ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque PsoriasisNCT07090330Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16 | Phase 2 | Active, not recruiting | Drug: ORKA-001 Induction Dose, ORKA-001 Maintenance Dose · Other: Placebo | Plaque Psoriasis | 80 | 2025-07-18 | 2026-03-25actual | — | 2026-07-01 |
| LLY | Eli Lilly and Company | $1.15T | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or OverweightNCT06588283Percentage of Participants Who Simultaneously Achieved Psoriasis Area and Severity Index (PASI) 100 and At Least 10% Weight Reduction | Phase 3 | Completed | Drug: Ixekizumab, Tirzepatide | Psoriasis, Obesity | 281 | 2024-09-30 | 2026-01-08actual | — | 2026-06-17 |
| GAIA | Gaia AG | $36M | Effectiveness of a Digital Health Application for PsoriasisNCT06027034Health-Related Quality of Life | Not applicable | Completed | Behavioral: Online program for psoriasis (GAIA-PSO-01) | Psoriasis | 348 | 2023-09-04 | 2024-12-31actual | — | 2026-06-16 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community SettingNCT05701995results2025-09-10Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Score of 0 or 1 at Week 16 | Phase 4 | Completed | Drug: Deucravacitinib · Other: Placebo | Psoriasis | 180 | 2023-01-31 | 2024-08-23actual | — | 2026-06-03 |
| LLY | Eli Lilly and Company | $1.15T | A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)NCT06857942Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) (0,1) | Phase 4 | Recruiting | Drug: Tirzepatide | Psoriasis, Overweight or Obesity | 200 | 2025-03-19 | May 2028 | ≤ 650 d | 2026-06-03 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body PsoriasisNCT07340216Concentration of Roflumilast and Roflumilast N-Oxide from plasma | Phase 1 | Completed | Drug: ARQ-154 Foam 0.3% | Psoriasis | 22 | 2025-12-15 | 2026-04-30actual | — | 2026-05-22 |
| BMY | Bristol-Myers Squibb | $134.9B | A Real-world Study to Evaluate the Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in France (RePhlect)NCT06701513observationalPhysician's Global Assessment (PGA) 0/1 response | — | Recruiting | Drug: Deucravacitinib | Psoriasis | 350 | 2025-01-29 | 2028-04-30 | in 619 d | 2026-05-18 |
| ABBV | AbbVie | $457.5B | Study to Assess the Safety and Change in Disease Symptoms of Risankizumab (Skyrizi) in Adult Participants With Moderate to Severe Plaque Psoriasis and Psoriatic ArthritisNCT04433442observationalNumber of Participants who Reported Adverse Events | — | Completed | — | Psoriasis, Psoriatic Arthritis | 2,324 | 2020-08-04 | 2025-06-13actual | — | 2026-04-27 |
| OGN | Organon and Co | $3.6B | Tapinarof for the Treatment of Plaque Psoriasis in Pediatric SubjectsNCT05172726Adverse Events (AEs) and Serious Adverse Events (SAEs) | Phase 3 | Active, not recruiting | Drug: tapinarof cream, 1% | Plaque Psoriasis | 58 | 2021-12-02 | Oct 2026 | ≤ 72 d | 2026-04-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital PsoriasisNCT06042920results2026-04-17Percentage of Participants Achieving Palmoplantar Psoriasis Area and Severity Index (Pp-PASI)-75 Response | Phase 4 | Terminatedsponsor's stated reason: Business objectives have changed | Drug: Deucravacitinib, Placebo | Palmoplantar Psoriasis, Genital Psoriasis | 130 | 2023-10-09 | 2025-04-25actual | — | 2026-04-17 |
| ABBV | AbbVie | $457.5B | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)NCT06333860Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) | Phase 4 | Completed | Drug: Risankizumab, Deucravacitinib | Moderate Plaque Psoriasis | 393 | 2024-05-10 | 2026-03-19actual | — | 2026-04-15 |
| BMY | Bristol-Myers Squibb | $134.9B | A Observational Study to Evaluate Deucravacitinib in Patients With Moderate Plaque Psoriasis in ChinaNCT06512337observationalNumber of participants achieving Static Physician's Global Assessment (sPGA) 0/1 score | — | Active, not recruiting | Drug: Deucravacitinib | Plaque Psoriasis | 153 | 2025-01-20 | 2027-03-11 | in 203 d | 2026-04-15 |
| ALMS | Alumis Inc | $2.1B | Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque PsoriasisNCT06846541To assess the long-term safety and tolerability of ESK-001 throughout the duration of the study | Phase 3 | Active, not recruiting | Drug: Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo | Plaque Psoriasis, Psoriasis (PsO), Psoriasis, Moderate Psoriasis, Severe Psoriasis | 1,680 | 2025-01-08 | Nov 2028 | ≤ 833 d | 2026-04-13 |
| 068270.KS | Celltrion | $30.7B | A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and PsNCT05866614observationalevaluation of adverse events of special interest (AESI) | — | Active, not recruiting | Drug: Remsima IV, Remsima SC | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis | 881 | 2023-01-13 | Mar 2027 | ≤ 223 d | 2026-03-31 |
| VNDA | Vanda Pharmaceuticals | $329M | Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05366855results2026-03-27Incidence of Adverse Events | Phase 3 | Terminatedsponsor's stated reason: AnaptysBio has concluded the GEMINI-2 trial, with all trial participants having been treated with imsidolimab for approximately six months and the furthest subject having been treated through 104 weeks. | Drug: Double-blind 200 mg imsidolimab, Open-label 200 mg imsidolimab, Imsidolimab 750 mg IV/200 mg SC · Other: Placebo, Standard of Care (SOC) | Generalized Pustular Psoriasis | 42 | 2022-04-21 | 2024-07-12actual | — | 2026-03-27 |
| ABBV | AbbVie | $457.5B | An Observational Study to Validate the Cumulative Life Course Impairment (CLCI) Instrument (DermCLCI-p) in Adult Participants With Moderate to Severe Chronic Plaque Psoriasis (PsO)NCT05959070observationalValidity of the Cumulative Life Course Impairment Instrument (DermCLCI-p) | — | Completed | — | Psoriasis | 154 | 2023-11-09 | 2025-03-21actual | — | 2026-03-25 |
| VNDA | Vanda Pharmaceuticals | $329M | Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPPNCT05352893results2026-03-17Percentage of Patients Achieving a GPPPGA Score of 0 (Clear) or 1 (Almost Clear) | Phase 3 | Completed | Drug: 750 mg Imsidolimab, 300 mg Imsidolimab · Other: Placebo | Generalized Pustular Psoriasis | 45 | 2022-04-14 | 2023-08-17actual | — | 2026-03-17 |
| ALM.MC | Almirall, S.A. | $2.2B | Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical PracticeNCT04203693results2026-03-02observationalCohort 1: Absolute Psoriasis Area and Severity Index (PASI) Score at Week 48 | — | Completed | Drug: Tildrakizumab | Plaque Psoriasis | 331 | 2019-10-30 | 2024-05-02actual | — | 2026-03-02 |
| ABBV | AbbVie | $457.5B | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisNCT05969223results2026-02-24Study-G: Percentage of Participants With Achievement of Static Physician Global Assessment of Genitalia (sPGA-G) of 0 or 1 at Week 16 | Phase 4 | Completed | Drug: Risankizumab, Placebo for Risankizumab | Genital Psoriasis, Scalp Psoriasis | 214 | 2023-08-10 | 2025-01-22actual | — | 2026-02-24 |
| 068270.KS | Celltrion | $30.7B | A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe PsoriasisNCT06630559Percent change from baseline in Psoriasis Area and Severity Index (PASI) score | Phase 3 | Active, not recruiting | Biological: CT-P55, EU-approved Cosentyx | Plaque Psoriasis | 153 | 2025-05-26 | 2026-02-18actual | — | 2026-02-23 |
| ABBV | AbbVie | $457.5B | Study to Evaluate the Effectiveness of Risankizumab in Participants With a Recent Diagnosis of Moderate Plaque Psoriasis in a Real-life Setting in GreeceNCT06247319observationalProportion of participants achieving Psoriasis Area and Severity Index (PASI) score less than or equal to 2 | — | Active, not recruiting | — | Moderate Plaque Psoriasis, Moderate Psoriasis, Psoriasis | 250 | 2024-04-29 | Oct 2027 | ≤ 437 d | 2026-02-04 |
| AMGN | Amgen | $229.9B | A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)NCT06122649Number of Participants Achieving at least a 75% Reduction (Improvement) From Baseline in Psoriasis Area and Severity Index (PASI) at Week 16 | Phase 3 | Completed | Drug: apremilast, Placebo | Plaque Psoriasis | 203 | 2023-11-27 | 2025-02-28actual | — | 2026-01-05 |
| AMGN | Amgen | $229.9B | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisNCT04175613Adverse Events (AEs) | Phase 3 | Completed | Drug: Apremilast | Psoriasis | 160 | 2019-12-20 | 2025-10-30actual | — | 2025-12-22 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Deucravacitinib in Participants With Moderate-to-Severe Plaque Psoriasis in GermanyNCT06104644observationalProportion of patients achieving an absolute Psoriasis Area Severity Index (aPASI) score ≤ 3 at Week 24 or nearest visit | — | Active, not recruiting | Drug: Deucravacitinib | Plaque Psoriasis | 550 | 2023-04-13 | 2025-08-18actual | — | 2025-12-04 |
| XNCR | Xencor, Inc. | $1.9B | Multiple Ascending-Dose Study of XmAb®27564 in Patients With Psoriasis or Atopic DermatitisNCT06005792To evaluate the safety and tolerability of multiple ascending dose subcutaneous (SC ) administration of XmAb27564 | Phase 1 | Terminatedsponsor's stated reason: Business Decision | Biological: XmAb27564, Placebo | Psoriasis, Atopic Dermatitis | 23 | 2022-10-10 | 2024-03-22actual | — | 2025-12-02 |
| BMY | Bristol-Myers Squibb | $134.9B | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in ItalyNCT07256015observationalThe percentage of participants still receiving deucravacitinib treatment | — | Recruiting | Drug: Deucravacitinib | Psoriasis | 200 | 2025-08-05 | 2027-07-05 | in 319 d | 2025-12-01 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate Effectiveness and Safety of BMS-986322 in Participants With Moderate-to-Severe PsoriasisNCT05730725results2025-11-25Percentage of Participants Achiving PASI-75 at Week 12 | Phase 2 | Completed | Drug: BMS-986322 · Other: Placebo | Psoriasis | 109 | 2023-04-03 | 2024-08-06actual | — | 2025-11-25 |
| ABBV | AbbVie | $457.5B | Observational Study of Patients With Moderate to Severe Chronic Plaque PsoriasisNCT03982394observationalPercentage of participants who achieved Psoriasis Area and Severity Index (PASI) 90 | — | Completed | — | Chronic Plaque Psoriasis | 2,759 | 2019-07-01 | 2025-09-02actual | — | 2025-11-17 |
| AMGN | Amgen | $229.9B | A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque PsoriasisNCT06088199Number of Participants With Treatment-emergent Adverse Events | Phase 3 | Active, not recruiting | Drug: Apremilast | Plaque Psoriasis | 51 | 2023-10-24 | 2026-08-06 | — | 2025-11-17 |
| SNY | Sanofi | — | A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque PsoriasisNCT06073119results2025-11-10Percentage of Participants With a 75% or Greater Psoriasis Area and Severity Index (PASI) Score Reduction From Baseline (PASI75) at Week 12 | Phase 2 | Completed | Drug: SAR441566, Placebo | Psoriasis | 221 | 2023-10-26 | 2024-11-13actual | — | 2025-11-10 |
| BMY | Bristol-Myers Squibb | $134.9B | Efficacy and Safety of Deucravacitinib Versus Placebo in Participants With Moderate-to-severe Scalp PsoriasisNCT05478499results2025-03-13Percentage of Participants With a Scalp-specific Physician Global Assessment Score of 0 or 1 (Ss-PGA 0/1) at Week 16 | Phase 4 | Completed | Drug: Deucravacitinib · Other: Placebo | Psoriasis | 154 | 2022-10-06 | 2024-01-11actual | — | 2025-10-28 |
| BMY | Bristol-Myers Squibb | $134.9B | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisNCT04036435Incidence of Adverse Events (AEs) | Phase 3 | Active, not recruiting | Drug: BMS-986165, Placebo | Psoriasis | 1,466 | 2019-08-12 | 2026-07-25 | — | 2025-10-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque PsoriasisNCT06176768results2025-10-15Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) | Phase 2 | Completed | Drug: LY3972406, Placebo | Plaque Psoriasis | 33 | 2023-12-06 | 2025-04-01actual | — | 2025-10-15 |
| SNY | Sanofi | — | A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate PsoriasisNCT05453942Number of participants with treatment-emergent adverse events (TEAE) including SAE and AESI | Phase 1 | Completed | Drug: SAR441566, Placebo | Psoriasis | 38 | 2022-07-12 | 2023-02-09actual | — | 2025-09-25 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study to Assess Treatment Satisfaction, Patient-reported Outcomes, Effectiveness, and Safety of a Fixed-dose Combination of Calcipotriene/Betamethasone Dipropionate PAD Cream in the Treatment of Mild-to-moderate Plaque Psoriasis of the Scalp in AdultsNCT05811234results2025-09-24observationalAbsolute Treatment Satisfaction Questionnaire for Medication Version 9 (TSQM-9) Domain Total Score at Week 12 | — | Completed | Drug: CAL/BDP PAD Cream | Plaque Psoriasis | 291 | 2023-06-13 | 2024-10-01actual | — | 2025-09-24 |
| ABBV | AbbVie | $457.5B | Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in TaiwanNCT04818385observationalThe Percentage of Participants who Achieved Psoriasis Area and Severity Index (PASI) 90 | — | Completed | — | Psoriasis | 240 | 2021-05-31 | 2025-08-01actual | — | 2025-09-17 |
| VNDA | Vanda Pharmaceuticals | $329M | A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular PsoriasisNCT03619902results2022-03-29Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale | Phase 2 | Completed | Biological: Imsidolimab | Generalized Pustular Psoriasis | 8 | 2019-01-30 | 2021-01-20actual | — | 2025-09-16 |
| AMGN | Amgen | $229.9B | Post-Marketing Surveillance Study of OTEZLANCT03284879observationalAdverse Events (AEs) | — | Completed | — | Psoriasis | 1,086 | 2017-09-05 | 2021-10-31actual | — | 2025-09-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in IndiaNCT05855967results2025-08-22Number of Participants Reporting Serious Adverse Events (SAEs), and Treatment Emergent Adverse Events (TEAEs) and AEs of Special Interests (AESIs) From Week 0 to Week 24 | Phase 4 | Completed | Drug: Ixekizumab | Plaque Psoriasis, Psoriatic Arthritis | 250 | 2023-06-27 | 2024-08-08actual | — | 2025-08-22 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of CareNCT04780516observationalPercentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) 0 or 1 | — | Active, not recruiting | — | Psoriasis | 141 | 2021-04-26 | 2024-01-02actual | — | 2025-08-13 |
| ABBV | AbbVie | $457.5B | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977NCT04862286Number of Participants With Adverse Events | Phase 3 | Active, not recruiting | Drug: Risankizumab | Psoriasis | 132 | 2021-07-24 | Apr 2028 | ≤ 619 d | 2025-08-12 |
| OGN | Organon and Co | $3.6B | Long Term Extension Study of Tapinarof for Plaque Psoriasis in Adults (3003)NCT04053387results2022-08-08Number of Subjects With Adverse Events and Serious Adverse Events | Phase 3 | Completed | Drug: tapinarof cream, 1% | Plaque Psoriasis | 763 | 2019-08-13 | 2021-04-06actual | — | 2025-08-06 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)NCT05028582results2025-07-17Achievement of Scalp Investigator Global Assessment (S-IGA) "Success" at Week 8 | Phase 3 | Completed | Drug: Roflumilast Foam 0.3%, Vehicle Foam | Scalp Psoriasis | 432 | 2021-08-24 | 2022-06-03actual | — | 2025-07-17 |
| AMGN | Amgen | $229.9B | A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of LifeNCT03774875results2022-01-13Percentage of Participants Who Achieved a ≥ 4-point Reduction From Baseline in Dermatology Life Quality Index (DLQI) at Week 16 | Phase 4 | Completed | Drug: Apremilast, Placebo | Psoriasis | 277 | 2019-03-28 | 2021-02-01actual | — | 2025-07-10 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess Deucravacitinib Post-marketing Surveillance in Participants With Psoriasis in JapanNCT05633264observationalIncidence of Adverse Events (AEs) | — | Completed | — | Psoriasis | 369 | 2022-12-05 | 2025-05-28actual | — | 2025-07-03 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study to Assess Patient-Reported Wellbeing Using Tildrakizumab in a Live SettingNCT06488170observationalChange From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score | — | Active, not recruiting | Drug: Tildrakizumab | Plaque Psoriasis | 42 | 2024-04-04 | Jan 2026 | — | 2025-06-24 |
| PFE | Pfizer | $155.3B | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)NCT03885089results2025-06-19observationalNumber of Participants With Adverse Drug Reactions | — | Completed | Drug: Infliximab [infliximab biosimilar 3] | Psoriasis Vulgaris, Psoriasis Arthropathica, Pustular Psoriasis, Erythrodermic Psoriasis | 10 | 2019-10-21 | 2024-03-08actual | — | 2025-06-19 |
| OGN | Organon and Co | $3.6B | Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque PsoriasisNCT04042103results2022-05-06Number of Participants That Experienced Adverse Events (AEs), Severe Adverse Events, and Serious Adverse Events (SAEs) | Phase 2 | Completed | Drug: Tapinarof cream, 1% | Plaque Psoriasis | 21 | 2019-07-23 | 2020-01-09actual | — | 2025-06-19 |
| ALMS | Alumis Inc | $2.1B | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque PsoriasisNCT05600036results2024-07-23To Compare the Psoriasis Area and Severity Index (PASI-75) Between Doses of ESK-001 and Placebo | Phase 2 | Completed | Drug: ESK-001, Placebo | Plaque Psoriasis | 228 | 2022-09-27 | 2023-06-29actual | — | 2025-06-18 |
| OGN | Organon and Co | $3.6B | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001)NCT03956355results2022-10-13Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation | Phase 3 | Completed | Drug: Tapinarof, Vehicle Cream | Plaque Psoriasis | 510 | 2019-05-21 | 2020-05-26actual | — | 2025-06-12 |
| OGN | Organon and Co | $3.6B | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3002)NCT03983980results2022-10-13Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation | Phase 3 | Completed | Drug: Tapinarof, Vehicle Cream | Plaque Psoriasis | 515 | 2019-06-06 | 2020-05-13actual | — | 2025-06-12 |
| OGN | Organon and Co | $3.6B | A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque PsoriasisNCT05680740results2024-07-08Percentage of Participants Who Achieve an Intertriginous PGA (iPGA) Score of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement | Phase 4 | Completed | Drug: VTAMA® (tapinarof) Cream 1% | Psoriasis | 34 | 2022-12-27 | 2023-05-18actual | — | 2025-06-12 |
| OGN | Organon and Co | $3.6B | A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck RegionNCT05789576results2024-08-09Percentage of Participants Who Achieve a Target Lesion Physician Global Assessment (PGA) Score in the Head and Neck Region of Clear (0) or Almost Clear (1) With a ≥ 2-grade Improvement | Phase 4 | Completed | Drug: VTAMA (tapinarof) cream, 1% | Psoriasis | 31 | 2023-03-13 | 2023-06-30actual | — | 2025-06-12 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Assess Deucravacitinib Safety in PregnancyNCT07017699observationalNumber of major congenital malformations among infants | — | Recruiting | Drug: Deucravacitinib, Other systemic treatments for PsO | Psoriasis (PsO) | 900 | 2025-03-21 | 2028-04-01 | in 590 d | 2025-06-12 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or PsoriasisNCT05796245results2025-06-04observationalIncidence Rate of Serious Infections | — | Completed | — | Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis | 2,207 | 2023-12-01 | 2024-03-14actual | — | 2025-06-04 |
| ABBV | AbbVie | $457.5B | A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease SymptomsNCT04435600results2025-05-20Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 (Defined as at Least 75% Improvement in PASI) | Phase 3 | Completed | Drug: Risankizumab, Ustekinumab | Psoriasis | 139 | 2020-07-14 | 2024-02-12actual | — | 2025-05-20 |
| ALM.MC | Almirall, S.A. | $2.2B | Observational Real-world Evidence (RWE) Study to Assess Patient-reported Wellbeing Using Tildrakizumab in Live Setting - POSITIVE StudyNCT04823247observationalChange From Baseline in 5-item World Health Organization Wellbeing Index (WHO-5) Score | — | Completed | Drug: Tildrakizumab | Plaque Psoriasis | 782 | 2021-11-22 | 2025-01-09actual | — | 2025-05-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study Comparing the Risk of Serious Infections and Malignancies With Deucravacitinib or Biologics in Japanese Patients With PsoriasisNCT06952465observationalParticipant baseline demographics | — | Active, not recruiting | Drug: Deucravacitinib · Biological: Any biologic treatment for psoriasis | Psoriasis | 2,000 | 2025-01-24 | 2031-11-30 | in 1,928 d | 2025-05-01 |
| CANF | Can-Fite BioPharma | — | A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNCT06643260Proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of ≥75% (PASI 75) | Phase 3 | Not yet recruiting | Drug: piclidenoson, Placebo | Plaque Psoriasis | 705 | Jun 2025 | Dec 2027 | ≤ 498 d | 2025-04-29 |
| LLY | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | $1.15T | A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque PsoriasisNCT05896527results2025-04-04Percentage of Participants Achieving ≥75% Reduction From Baseline in Psoriasis Area and Severity Index (PASI-75) at Week 12 | Phase 2 | Completed | Drug: DC-806 · Other: Placebo | Plaque Psoriasis | 229 | 2023-05-02 | 2024-03-25actual | — | 2025-04-04 |
| ALDX | Aldeyra Therapeutics, Inc. | $94M | A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque PsoriasisNCT04908514results2025-03-11Change From Baseline in the Psoriasis Area and Severity Index (PASI) | Phase 2 | Completed | Drug: ADX-629 | Plaque Psoriasis | 10 | 2021-05-07 | 2022-01-21actual | — | 2025-03-11 |
| LLY | DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company | $1.15T | A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque PsoriasisNCT06808815Part 1: Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug. | Phase 1 | Completed | Drug: DC-806 · Other: Placebo | Plaque Psoriasis | 104 | 2021-09-22 | 2022-08-23actual | — | 2025-02-05 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study of Tildrakizumab in the Treatment of Genital Psoriasis (CZATCH-Genital-PsO)NCT06029257observationalPercentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of "Clear" (0) or "Almost Clear" (1) | — | Recruiting | Drug: Tildrakizumab | Genital Psoriasis | 110 | 2023-11-14 | Mar 2026 | — | 2025-01-29 |
| ALM.MC | Almirall, S.A. | $2.2B | A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque PsoriasisNCT06030076observationalTreatment Satisfaction Questionnaire for Medication-11 (TSQM-11) Score | — | Recruiting | Drug: Tildrakizumab | Plaque Psoriasis | 50 | 2023-09-06 | Oct 2025 | — | 2025-01-29 |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.3B | Open-Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque PsoriasisNCT04286607Occurrence of treatment emergent AEs (TEAEs) | Phase 3 | Completed | Drug: Topical roflumilast | Chronic Plaque Psoriasis | 333 | 2020-02-12 | 2024-01-22actual | — | 2025-01-07 |
| AMGN | Amgen | $229.9B | Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisNCT03701763results2023-12-07Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 | Phase 3 | Completed | Drug: Apremilast (CC-10004) · Other: Placebo | Psoriasis | 245 | 2018-12-19 | 2022-04-25actual | — | 2024-12-16 |
| AMGN | Amgen | $229.9B | A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisNCT04607980results2023-12-15PASI Percent Change From Baseline to Week 12 | Phase 3 | Completed | Drug: ABP 654, Ustekinumab | Plaque Psoriasis | 563 | 2020-11-11 | 2022-01-13actual | — | 2024-12-12 |
| ABBV | AbbVie | $457.5B | A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )NCT03047395results2024-12-11Number of Participants With Serious Adverse Events and Non-Serious Adverse Events | Phase 3 | Completed | Biological: risankizumab | Psoriasis | 2,170 | 2017-02-27 | 2023-11-29actual | — | 2024-12-11 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study on the Safety of Deucravacitinib Exposure in Pregnant Women and Their OffspringNCT06710470observationalNumber of infants born with Major Congenital Malformations (MCMs) | — | Active, not recruiting | Drug: Deucravacitinib, Systemic psoriasis medications · Other: No systemic medications | Psoriasis | 833 | 2024-08-02 | 2027-01-31 | in 164 d | 2024-11-29 |
| ABBV | AbbVie | $457.5B | Effect of Long-term Psoriasis on Patients' Life - CORONATENCT05555953observationalCORONATE Questionnaire Score | — | Completed | — | Psoriasis | 543 | 2023-01-26 | 2024-10-17actual | — | 2024-10-26 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe PsoriasisNCT01096862Change from baseline to the end of treatment in Psoriasis Area Severity Index (PASI) score | Phase 2 | Completed | Drug: peficitinib, Placebo | Psoriasis | 124 | 2010-03-23 | 2011-07-27actual | — | 2024-10-21 |
| PFE | Pfizer | $155.3B | A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.NCT05375955results2024-10-02Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only | Phase 2 | Completed | Drug: PF-07038124 ointment 0.01%, Vehicle ointment, PF-07038124 ointment 0.03%, PF-07038124 ointment 0.06% | Atopic Dermatitis, Plaque Psoriasis | 263 | 2022-09-26 | 2023-07-31actual | — | 2024-10-02 |
| PFE | Wyeth is now a wholly owned subsidiary of Pfizer | $155.3B | Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With PsoriasisNCT00563524results2024-08-23Number of Participants With Treatment-Emergent Adverse Events (AEs) And Serious Adverse Events (SAEs) | Phase 1 | Completed | Drug: ILV-094 | Psoriasis | 76 | 2007-12-20 | 2010-06-14actual | — | 2024-08-23 |
| 068270.KS | Celltrion | $30.7B | To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque PsoriasisNCT05495568To demonstrate the pharmacokinetics (PK) similarity between patients receiving Humira continuously and those who alternate between Humira and CT-P17 in terms of Area under the concentration-time curve over the dosing interval (AUCtau, 25-27) | Phase 3 | Completed | Biological: CT-P17, EU-approved Humira | Moderate to Severe Chronic Plaque Psoriasis | 367 | 2022-11-07 | 2023-08-14actual | — | 2024-08-21 |
| OGN | Organon and Co | $3.6B | Elocon vs Fluticasone in Localized Psoriasis (P03197)NCT00763529Reduction in mean symptom scores for erythema, induration, pruritus, and scaling on Day 4. | Phase 4 | Completed | Drug: Mometasone, Fluticasone | Psoriasis | 245 | 2003-01-01 | 2005-01-01actual | — | 2024-08-15 |
| LLY | Eli Lilly and Company | $1.15T | A Safety Study of Mirikizumab (LY3074828)NCT01947933results2024-07-25Number of Participants With One or More Adverse Event(s) (AEs) Considered by the Investigator to Be Related to Study Drug Administration | Phase 1 | Completed | Biological: Mirikizumab- IV, Mirikizumab - SC, Placebo - IV | Psoriasis | 45 | Oct 2013 | Feb 2015actual | — | 2024-07-25 |
| BMY | Bristol-Myers Squibb | $134.9B | A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque PsoriasisNCT05744466observationalChange in body surface area (BSA) | — | Recruiting | Drug: Deucravacitinib, Apremilast | Psoriasis | 1,500 | 2022-09-30 | 2027-12-10 | in 477 d | 2024-07-23 |
| PFE | Pfizer | $155.3B | Study Evaluating Single Dose Of ILV-095 In Psoriasis SubjectsNCT01010542results2024-07-03Percentage of Participants With 50 Percent Improvement From Baseline in Total Psoriasis Area Severity Index (PASI) Score at Week 2 | Phase 1 | Terminatedsponsor's stated reason: See termination reason in detailed description. | Drug: ILV-095 300 mg in a 4 to 1 ratio, ILV-095 300 mg in a 4 to 1 ratio | Plaque Psoriasis | 39 | 2009-12-01 | 2011-05-20actual | — | 2024-07-03 |
| ABBV | AbbVie | $457.5B | Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar InvolvementNCT04713592results2024-06-14Percentage of Participants Achieving Palmoplantar Investigator's Global Assessment (ppIGA) of "Clear" or "Almost Clear" (0 or 1) With at Least a 2-point Reduction From Baseline at Week 16 | Phase 3 | Completed | Drug: Placebo for Risankizumab, Risankizumab | Psoriasis | 174 | 2021-02-26 | 2023-04-20actual | — | 2024-06-14 |
| AMGN | Amgen | $229.9B | Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in SpainNCT03539419observationalPercentage of subjects achieving PBI ≥ 1 | — | Completed | — | Psoriasis | 153 | 2018-06-12 | 2019-11-02actual | — | 2024-06-05 |
| AMGN | Amgen | $229.9B | Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and EfficacyNCT03721172results2021-05-17Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 During the Placebo-Controlled Phase | Phase 3 | Completed | Drug: Apremilast · Other: Placebo | Psoriasis | 595 | 2019-03-11 | 2020-03-06actual | — | 2024-05-29 |
| AMGN | Amgen | $229.9B | An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital PsoriasisNCT03777436results2022-12-15Percentage of Participants With a Modified sPGA-G Response at Week 16 | Phase 3 | Completed | Drug: Apremilast · Other: Placebo | Psoriasis | 289 | 2019-02-11 | 2021-09-23actual | — | 2024-05-14 |
| AMGN | Amgen | $229.9B | Observational Study of Apremilast in Patients With Psoriasis in The NetherlandsNCT02652494observationalPercentage of patients with Dermatology Life Quality Index (DLQI) ≤ 5 points | — | Completed | — | Psoriasis | 154 | 2016-02-22 | 2019-12-31actual | — | 2024-05-13 |
| ABBV | AbbVie | $457.5B | Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic TherapyNCT04908475results2024-04-30Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 90 (Defined as at Least 90% Improvement in PASI From Baseline) in Intent to Treat Population at Week 16 (ITT_A) | Phase 4 | Completed | Drug: Risankizumab, Apremilast | Psoriasis | 352 | 2021-06-09 | 2023-04-20actual | — | 2024-04-30 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of the Comparative Effectiveness of Deucravacitinib in Adults With Plaque Psoriasis in Japan (RePhlect)NCT06382987observationalChange in percent Body Surface Area (BSA) involved affected by plaque psoriasis from baseline to follow up in participants treated with deucravacitinib. | — | Recruiting | Drug: Deucravacitinib, Apremilast | Plaque Psoriasis | 600 | 2024-01-22 | 2029-12-31 | in 1,229 d | 2024-04-25 |
| ABBV | AbbVie | $457.5B | Chronic Plaque Psoriasis (Ps) RegistryNCT00799877observationalIncidence of Serious Adverse Events | — | Completed | — | Chronic Plaque Psoriasis | 6,065 | 2008-09-26 | 2023-02-13actual | — | 2024-03-15 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Psoriasis is matched — 17 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Psoriasis
- Plaque Psoriasis
- Chronic Plaque Psoriasis
- Psoriasis Vulgaris
- Generalized Pustular Psoriasis
- Genital Psoriasis
- Moderate to Severe Plaque Psoriasis
- Nail Psoriasis
- Plaque Psoriasis Vulgaris
- Erythrodermic Psoriasis
- Moderate Plaque Psoriasis
- Moderate Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
- Plaque-type Psoriasis
- Psoriasis (PsO)
- Pustular; Psoriasis, Palmaris Et Plantaris
- Scalp Psoriasis
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Psoriasis” (a text search, wider than this page)